Evidence map›Paper›PMID 40113668›Full record

ReviewGeroScience2025

Cerebromicrovascular senescence in vascular cognitive impairment: does accelerated microvascular aging accompany atherosclerosis?

Anna Ungvari, Ádám Nyúl-Tóth, Roland Patai, Boglarka Csik, Rafal Gulej, Dorina Nagy, Santny Shanmugarama, Zoltán Benyó, Tamas Kiss, Zoltan Ungvari and 1 more

Abstract readReview
In one paragraph

Review in GeroScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Recent advances in biomarkers for cardiac fibrosis.Frontiers in cardiovascular medicine · 2026
    Review
  10. Review
  11. Review
  12. Senotherapeutics for Brain Aging Management.Neurology international · 2025
    Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Anna Ungvari *Institute of Preventive Medicine and Public Health, Semmelweis University, Budapest, Hungary. Ungann2004@gmail.com.ORCID 0009-0001-5053-2828
Ádám Nyúl-Tóth *Vascular Cognitive Impairment, Neurodegeneration and Healthy Brain Aging Program, Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Roland Patai *Vascular Cognitive Impairment, Neurodegeneration and Healthy Brain Aging Program, Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Boglarka CsikInstitute of Preventive Medicine and Public Health, Semmelweis University, Budapest, Hungary.
Rafal GulejVascular Cognitive Impairment, Neurodegeneration and Healthy Brain Aging Program, Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Dorina NagyVascular Cognitive Impairment, Neurodegeneration and Healthy Brain Aging Program, Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Santny ShanmugaramaVascular Cognitive Impairment, Neurodegeneration and Healthy Brain Aging Program, Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Zoltán BenyóInstitute of Translational Medicine, Semmelweis University, Budapest, Hungary.
Tamas KissCerebrovascular and Neurocognitive Diseases Research Group, HUN-REN, Semmelweis University, Budapest, Hungary.
Zoltan UngvariVascular Cognitive Impairment, Neurodegeneration and Healthy Brain Aging Program, Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Anna CsiszarVascular Cognitive Impairment, Neurodegeneration and Healthy Brain Aging Program, Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.

Funding

Cerebral microhemorrhages and gait dysfunction in agingR01AG055395 · NIA · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI CSISZAR, ANNA · 2017 to 2025
$2.3M
Age-related vascular cognitive impairment: role of endothelial senescenceR01AG068295 · NIA · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI CSISZAR, ANNA, UNGVARI, ZOLTAN ISTVAN · 2020 to 2024
$1.8M
The role of IGF-1 signaling in vascular smooth muscle cells in age-related vascular cognitive impairment and dementiaR01AG070915 · NIA · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI CONLEY, SHANNON M · 2021 to 2025
$1.8M
Radiation-induced astrocyte dysfunction and cognitive declineR01NS100782 · NINDS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI UNGVARI, ZOLTAN ISTVAN · 2018 to 2022
$1.7M
Chemotherapy-induced vascular cognitive impairment: role of endothelial senescenceR01CA255840 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI CSISZAR, ANNA · 2021 to 2025
$1.6M
Cerebromicrovascular rejuvenation by heterochronic blood exchangeRF1AG072295 · NIA · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI CSISZAR, ANNA, UNGVARI, ZOLTAN ISTVAN · 2021 to 2021
$1.4M
Cerebromicrovascular rejuvenation by heterochronic blood exchangeR01AG072295 · NIA · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI CSISZAR, ANNA, UNGVARI, ZOLTAN ISTVAN · 2024 to 2025
$875k
NCI NIH HHS R01 CA255840NCI NIH HHS R01CA255840NIA NIH HHS R01 AG055395NIA NIH HHS R01AG055395NIA NIH HHS R01 AG068295NIA NIH HHS R01AG068295NIA NIH HHS R01 AG070915NIA NIH HHS R01AG070915NIA NIH HHS R01 AG072295NIA NIH HHS R01AG072295NIA NIH HHS RF1 AG072295NINDS NIH HHS R01 NS100782NINDS NIH HHS R01NS100782
6 · The paper itself

Abstract

Vascular cognitive impairment (VCI) is a leading cause of age-related cognitive decline, driven by cerebrovascular dysfunction and cerebral small vessel disease (CSVD). Emerging evidence suggests that cerebromicrovascular endothelial senescence plays an important role in the pathogenesis of VCI by promoting cerebral blood flow dysregulation, neurovascular uncoupling, blood-brain barrier (BBB) disruption, and the development of cerebral microhemorrhages (CMHs). This review explores the concept of cerebromicrovascular senescence as a continuum of vascular aging, linking macrovascular atherosclerosis with microvascular dysfunction. It examines the mechanisms by which endothelial senescence drives neurovascular pathology and highlights the impact of cardiovascular risk factors in accelerating these processes. We examine preclinical and clinical studies that provide compelling evidence that atherosclerosis-induced microvascular senescence exacerbates cognitive impairment. In particular, findings suggest that targeting senescent endothelial cells through senolytic therapy can restore cerebrovascular function and improve cognitive outcomes in experimental models of atherosclerosis. Given the growing recognition of microvascular senescence as a therapeutic target, further research is warranted to explore novel interventions such as senolytics, anti-inflammatory agents, and metabolic modulators. The development of circulating biomarkers of vascular senescence (e.g., senescence-associated secretory phenotype [SASP] components and endothelial-derived extracellular vesicles) could enable early detection and risk stratification in individuals at high risk for VCI. Additionally, lifestyle modifications, including the Mediterranean diet, hold promise for delaying endothelial senescence and mitigating cognitive decline. In conclusion, cerebromicrovascular senescence is a key mechanistic link between atherosclerosis and cognitive impairment. Addressing microvascular aging as a modifiable risk factor through targeted interventions offers a promising strategy for reducing the burden of VCI and preserving cognitive function in aging populations.

Indexed as

AgingAtherosclerosisCerebral Small Vessel DiseasesCognitive DysfunctionMicrovesselsAnimalsBlood-Brain BarrierCellular SenescenceCerebrovascular CirculationHumansRisk FactorsAgingArteriosclerosisAtherogenesisAtherosclerosisCerebral circulationEndothelial biomarkersInflammationOxidative stressPeripheral artery diseaseSenolytics

Identifiers

PMID40113668
PMCPMC12397478

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.